GleamWall
中文EN

DNA Ginkgo Bioworks Holdings, Inc.

Biological Products, (No Diagnostic Substances) · NYSE · SEC CIK 1830214 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-33.1%
TTM net income YoY26.1%
TTM EPS YoY—
Revenue 3-yr CAGR-31.6%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-242.5%
Net margin-249.2%
FCF margin-172.3%
EBITDA margin-190.5%

Returns

ROE-52.7%
ROA-23.5%
ROIC (approx.)-51.0%
Asset turnover0.09x

Leverage & solvency

Liabilities / assets58.4%
Debt / equity0.00x
Current ratio4.72x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.67x
Accruals ratio-7.9%
Payout ratio—
Capex / revenue6.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$27.71M$20.16M$19.47M$33.40M$29.38M$39.13M$38.23M$43.85M
Cost of revenue$1.81M$1.72M$3.10M—$4.62M$5.38M$4.09M—
Gross profit$25.91M$18.44M$16.38M—$24.75M$33.75M$34.14M—
R&D expense$40.95M$46.21M$49.92M$50.13M$69.35M$53.37M$70.92M$76.38M
SG&A expense$28.59M$30.77M$37.83M$46.01M$36.99M$34.98M$39.72M$57.30M
Operating income-$43.63M-$58.55M-$71.37M-$70.75M-$82.31M-$58.16M-$80.97M-$103.61M
Interest expense———————$31.37M
Pretax income-$41.26M-$57.19M-$76.14M-$103.55M-$73.35M-$53.48M-$83.22M-$107.86M
Income tax-$271,000$128,000-$80,000-$643,000$1,000-$283,000$88,000-$325,000
Net income-$40.98M-$46.71M-$82.59M-$80.75M-$80.75M-$60.30M-$90.96M-$107.53M
EBITDA-$31.59M-$46.23M-$58.58M-$55.46M-$68.68M-$42.91M-$66.15M-$87.95M
EPS (basic)-0.64-0.75-1.39—-1.45-1.10-1.68—
EPS (diluted)————-1.45-1.10-1.68—
Weighted avg. shares (diluted)————55.63M54.86M54.24M—
Banking
Net interest income$3.06M$3.23M$3.60M—$5.74M$6.08M$6.08M—
Loans, net$7.50M$7.50M$7.50M$9.70M$22.00M$22.00M$24.90M$25.10M
Balance sheet
Cash & equivalents$84.50M$84.53M$143.86M$167.20M$111.06M$203.57M$312.42M$561.57M
Short-term investments———$255.42M$384.42M$355.79M$12.84M$0
Receivables$11.48M$13.01M$19.82M$24.03M$21.43M$22.15M$26.29M$21.86M
Current assets$310.84M$332.54M$409.95M$471.84M$506.08M$523.02M$564.53M$602.74M
PP&E, net$152.35M$157.19M$163.02M$167.37M$176.58M$186.35M$197.83M$203.72M
Goodwill———————$0
Intangibles$39.73M$44.39M$48.86M$53.48M$61.52M$66.15M$68.76M$72.51M
Total assets$944.45M$990.05M$1.03B$1.12B$1.19B$1.23B$1.29B$1.38B
Current liabilities$65.85M$72.74M$79.59M$95.97M$115.28M$96.72M$115.67M$107.27M
Total liabilities$551.82M$569.76M$589.92M$611.11M$629.38M$618.06M$646.04M$661.39M
Shareholders' equity$392.64M$420.28M$443.15M$508.59M$559.78M$612.95M$647.43M$716.06M
Shares outstanding64.50M63.71M61.66M58.21M56.84M55.43M54.70M54.37M
Cash flow statement
Operating cash flow-$28.35M-$44.27M-$46.69M-$47.68M-$31.61M-$40.25M-$51.52M-$42.44M
Capital expenditure$2.00M$2.62M$1.93M$5,000$0$38,000$7.62M$13.71M
Free cash flow-$30.35M-$46.89M-$48.62M-$47.68M-$31.61M-$40.29M-$59.14M-$56.15M
Investing cash flow-$24.10M$11.09M$23.13M$95.10M-$72.82M-$63.89M-$198.68M-$13.09M
Financing cash flow$6.50M$16.49M-$19,000$8.14M$9.94M-$98,000-$207,000-$203,000
Depreciation & amortization$12.04M$12.31M$12.80M$15.29M$13.62M$15.25M$14.82M$15.65M
Stock-based compensation$7.67M$7.59M$15.85M$21.03M$15.04M$18.80M$17.39M$20.56M

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.